1. Home
  2. DFLI vs JAGX Comparison

DFLI vs JAGX Comparison

Compare DFLI & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dragonfly Energy Holdings Corp. (NV)

DFLI

Dragonfly Energy Holdings Corp. (NV)

HOLD

Current Price

$2.32

Market Cap

5.0M

Sector

Technology

ML Signal

HOLD

Logo Jaguar Health Inc.

JAGX

Jaguar Health Inc.

HOLD

Current Price

$2.38

Market Cap

4.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DFLI
JAGX
Founded
2020
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Electronic Components
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.0M
4.4M
IPO Year
2021
2014

Fundamental Metrics

Financial Performance
Metric
DFLI
JAGX
Price
$2.32
$2.38
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
253.6K
★ 2.0M
Earning Date
11-13-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 82.42
EPS
★ N/A
N/A
Revenue
★ $58,630,000.00
$11,511,000.00
Revenue This Year
N/A
$77.78
Revenue Next Year
$61.43
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 15.77
N/A
52 Week Low
$0.41
$0.20
52 Week High
$5.15
$41.53

Technical Indicators

Market Signals
Indicator
DFLI
JAGX
Relative Strength Index (RSI) 57.31 45.70
Support Level $1.85 $2.12
Resistance Level $2.88 $3.07
Average True Range (ATR) 0.26 0.52
MACD 0.02 -0.40
Stochastic Oscillator 53.67 10.58

Price Performance

Historical Comparison
DFLI
JAGX

About DFLI Dragonfly Energy Holdings Corp. (NV)

Dragonfly Energy Holdings Corp is engaged in the design, assembly, and sale of lithium-ion batteries, mainly lithium iron phosphate (LFP) batteries, for applications in recreational vehicles, marine, industrial, and other markets. The company operates through two segments: direct-to-consumer (DTC), which sells Battle Born branded batteries, and OEM, which supplies Dragonfly branded batteries to original equipment manufacturers.

About JAGX Jaguar Health Inc.

Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

Share on Social Networks: